Skip to main content

Clinical TrialsSearch 1M+ trials from global registries Drug IntelligenceFollow pipelines from discovery to approval

Global ApprovalsTrack regulatory decisions across 12+ agencies

US FDA Drugs EU EMA Drugs Singapore HSA Drugs China NMPA Drugs Australia TGA Drugs Canada HC Drugs Spain CIMA-AEMPS Drugs UK EMC Drugs Saudi SFDA Drugs Malaysia NPRA Drugs Philippines FDA Drugs Kenya PPB Drugs

AI-Powered ResearchDiscover powerful insights with advanced AI analysis tools for clinical trials.Learn more →Premium AccessGet unlimited access to our comprehensive pharmaceutical database and analytics.Subscribe →

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Approvals/CIMA-AEMPS/VIMPAT 150 MG COMPRIMIDOS RECUBIERTOS CON PELICULA

Approved

STANDARD

VIMPAT 150 MG COMPRIMIDOS RECUBIERTOS CON PELICULA

Ucb Pharma🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Jun 11, 2025
Approval ID: fc873af0f897fa97
Company: Ucb Pharma
Type: Standard

Approval Details

Approval Id: fc873af0f897fa97
Drug Cima Aemps Name: VIMPAT 150 MG COMPRIMIDOS RECUBIERTOS CON PELICULA
Register Number: 08470008IP
Holder Company Name: Ucb Pharma
Marketing Company Name: Melyfarma S.L.
Holder Company Detail Path: /organization/61e9bd4d83a8633f/ucb-pharma-sa
Authorization Date: 2025-06-11
Dosage Form: COMPRIMIDO RECUBIERTO CON PELÍCULA
Dose: 150 mg
Route Of Administration: VÍA ORAL
Prescription Type: Medicamento Sujeto A Prescripción Médica
Commercialized: No
Company Name: Ucb Pharma
Company Detail Path: /organization/61e9bd4d83a8633f/ucb-pharma-sa

Company Information

Pharmaceutical Company Name: UCB PHARMA SA
Country Name: Belgium
City Name: colombes,ile de france,country_fr
Address: DEFENSE OUEST
Website: https://www.ucb-iberia.com/home

Active Ingredients

LACOSAMIDA

150 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Jun 11, 2025

Approval ID

fc873af0f897fa97

Type

Standard

Back to CIMA-AEMPS Approvals

VIMPAT 150 MG COMPRIMIDOS RECUBIERTOS CON PELICULA - CIMA-AEMPS Drug Approval Details